Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 11.94
(-0.5%)
AUD 11.94
(-0.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 28.11 Million AUD | -5.96% |
| 2023 | 29.89 Million AUD | 55.25% |
| 2022 | 19.25 Million AUD | 95.88% |
| 2021 | 9.83 Million AUD | 3.75% |
| 2020 | 9.47 Million AUD | 83.43% |
| 2019 | 5.16 Million AUD | 48.07% |
| 2018 | 3.48 Million AUD | 10.3% |
| 2017 | 3.16 Million AUD | 37.3% |
| 2016 | 2.3 Million AUD | -5.53% |
| 2015 | 2.43 Million AUD | 41.3% |
| 2014 | 1.72 Million AUD | -12.64% |
| 2013 | 1.97 Million AUD | -16.22% |
| 2012 | 2.35 Million AUD | -37.24% |
| 2011 | 3.75 Million AUD | 21.97% |
| 2010 | 3.08 Million AUD | -32.48% |
| 2009 | 4.56 Million AUD | 44.56% |
| 2008 | 3.15 Million AUD | 29.73% |
| 2007 | 2.43 Million AUD | -21.06% |
| 2006 | 3.08 Million AUD | 18.48% |
| 2005 | 2.6 Million AUD | 86.82% |
| 2004 | 1.39 Million AUD | 160.05% |
| 2003 | 535.45 Thousand AUD | 153.98% |
| 2002 | 210.82 Thousand AUD | -33.76% |
| 2001 | 318.26 Thousand AUD | 157.62% |
| 2000 | 123.53 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 33.03 Million AUD | 0.0% |
| 2024 Q4 | 28.11 Million AUD | 0.0% |
| 2024 FY | 28.11 Million AUD | -5.96% |
| 2023 FY | 29.89 Million AUD | 55.25% |
| 2023 Q2 | 21.12 Million AUD | 0.0% |
| 2023 Q4 | 29.89 Million AUD | 0.0% |
| 2022 FY | 19.25 Million AUD | 95.88% |
| 2022 Q4 | 19.25 Million AUD | 0.0% |
| 2022 Q2 | 8.36 Million AUD | 0.0% |
| 2021 Q4 | 9.83 Million AUD | 0.0% |
| 2021 FY | 9.83 Million AUD | 3.75% |
| 2021 Q2 | 9.79 Million AUD | 0.0% |
| 2020 Q4 | 7.87 Million AUD | 0.0% |
| 2020 Q2 | 4.05 Million AUD | 0.0% |
| 2020 FY | 9.47 Million AUD | 83.43% |
| 2019 FY | 5.16 Million AUD | 48.07% |
| 2019 Q2 | 2.56 Million AUD | 0.0% |
| 2019 Q4 | 5.16 Million AUD | 0.0% |
| 2018 FY | 3.48 Million AUD | 10.3% |
| 2018 Q4 | 3.48 Million AUD | 0.0% |
| 2018 Q2 | 2.76 Million AUD | 0.0% |
| 2017 Q4 | 3.16 Million AUD | 0.0% |
| 2017 Q2 | 2.27 Million AUD | 0.0% |
| 2017 FY | 3.16 Million AUD | 37.3% |
| 2016 Q4 | 2.3 Million AUD | 0.0% |
| 2016 FY | 2.3 Million AUD | -5.53% |
| 2016 Q2 | 2.49 Million AUD | 0.0% |
| 2015 Q2 | 1.79 Million AUD | 0.0% |
| 2015 FY | 2.43 Million AUD | 41.3% |
| 2015 Q4 | 2.43 Million AUD | 0.0% |
| 2014 FY | 1.72 Million AUD | -12.64% |
| 2014 Q2 | 1.81 Million AUD | 0.0% |
| 2014 Q4 | 1.72 Million AUD | 0.0% |
| 2013 Q4 | 1.97 Million AUD | 1.5% |
| 2013 FY | 1.97 Million AUD | -16.22% |
| 2013 Q3 | 1.94 Million AUD | -35.09% |
| 2013 Q2 | 2.99 Million AUD | 0.0% |
| 2013 Q1 | 2.99 Million AUD | 27.15% |
| 2012 FY | 2.35 Million AUD | -37.24% |
| 2012 Q4 | 2.35 Million AUD | 0.0% |
| 2011 FY | 3.75 Million AUD | 21.97% |
| 2011 Q4 | 3.75 Million AUD | 0.0% |
| 2010 FY | 3.08 Million AUD | -32.48% |
| 2010 Q4 | 3.08 Million AUD | 0.0% |
| 2009 FY | 4.56 Million AUD | 44.56% |
| 2009 Q4 | 4.56 Million AUD | 0.0% |
| 2008 FY | 3.15 Million AUD | 29.73% |
| 2008 Q4 | 3.15 Million AUD | 0.0% |
| 2007 Q4 | 2.43 Million AUD | 0.0% |
| 2007 FY | 2.43 Million AUD | -21.06% |
| 2006 FY | 3.08 Million AUD | 18.48% |
| 2006 Q4 | 3.08 Million AUD | 0.0% |
| 2005 FY | 2.6 Million AUD | 86.82% |
| 2005 Q4 | 2.6 Million AUD | 0.0% |
| 2004 Q4 | 1.39 Million AUD | 0.0% |
| 2004 FY | 1.39 Million AUD | 160.05% |
| 2003 Q4 | 535.45 Thousand AUD | 0.0% |
| 2003 FY | 535.45 Thousand AUD | 153.98% |
| 2002 FY | 210.82 Thousand AUD | -33.76% |
| 2002 Q4 | 210.82 Thousand AUD | 0.0% |
| 2001 FY | 318.26 Thousand AUD | 157.62% |
| 2000 FY | 123.53 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -564.725% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -9061.569% |
| Zelira Therapeutics Limited | 9.35 Million AUD | -200.453% |
| Biome Australia Limited | 5.37 Million AUD | -423.186% |
| Patrys Limited | 691.36 Thousand AUD | -3966.185% |
| Orthocell Limited | 22.08 Million AUD | -27.304% |
| Imugene Limited | 33.14 Million AUD | 15.18% |
| Noxopharm Limited | 1.28 Million AUD | -2081.583% |
| PYC Therapeutics Limited | 10.18 Million AUD | -176.04% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | -119.573% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -1108.833% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -1628.996% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -2300.586% |
| CSL Limited | 27.88 Billion AUD | 99.899% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -1266.901% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -7529.933% |
| Starpharma Holdings Limited | 8.69 Million AUD | -223.203% |
| Nanollose Limited | 465.64 Thousand AUD | -5937.282% |
| Memphasys Limited | 5.59 Million AUD | -402.686% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -6413.028% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -32709.522% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -720.363% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -653.258% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -2588.556% |
| Race Oncology Limited | 1.91 Million AUD | -1366.908% |
| Nyrada Inc. | 855.63 Thousand AUD | -3185.542% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 88.728% |
| Dimerix Limited | 13.89 Million AUD | -102.347% |
| PharmAust Limited | 896.6 Thousand AUD | -3035.396% |
| Immutep Limited | 10.97 Million AUD | -156.04% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -237.41% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -418.131% |
| BTC Health Limited | 203.94 Thousand AUD | -13683.995% |
| Acrux Limited | 5.68 Million AUD | -394.324% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 34.26% |
| Biotron Limited | 737.5 Thousand AUD | -3711.78% |
| Tissue Repair Ltd | 1.35 Million AUD | -1980.99% |
| AdAlta Limited | 3.54 Million AUD | -693.557% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 37.085% |
| Hexima Limited | 248.67 Thousand AUD | -11205.016% |
| AnteoTech Limited | 4.07 Million AUD | -589.826% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -684.305% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | -76.88% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -2885.766% |
| Actinogen Medical Limited | 1.61 Million AUD | -1640.296% |
| Immuron Limited | 2.84 Million AUD | -889.683% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -1058.444% |